A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts

5 analysts have expressed a variety of opinions on Ionis Pharmaceuticals IONS over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $65.4, accompanied by a high estimate of $77.00 and a low estimate of $55.00. Highlighting a 1.51% decrease, the current average has fallen from the previous average price target of $66.40.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Ionis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ionis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Ionis Pharmaceuticals analyst ratings.

Get to Know Ionis Pharmaceuticals Better

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals: Financial Performance Dissected

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, Ionis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 19.55% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Ionis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -29.42%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -23.66%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.43%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.47, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Basics of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.